DE60224521D1 - N-aroyl zyklische amine - Google Patents
N-aroyl zyklische amineInfo
- Publication number
- DE60224521D1 DE60224521D1 DE60224521T DE60224521T DE60224521D1 DE 60224521 D1 DE60224521 D1 DE 60224521D1 DE 60224521 T DE60224521 T DE 60224521T DE 60224521 T DE60224521 T DE 60224521T DE 60224521 D1 DE60224521 D1 DE 60224521D1
- Authority
- DE
- Germany
- Prior art keywords
- cyclic amine
- aroyl cyclic
- aroyl
- amine
- cyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0111189 | 2001-05-05 | ||
GBGB0111189.7A GB0111189D0 (en) | 2001-05-05 | 2001-05-05 | Compounds |
GB0111184 | 2001-05-05 | ||
GB0111184A GB0111184D0 (en) | 2001-05-05 | 2001-05-05 | Compounds |
GB0121303A GB0121303D0 (en) | 2001-09-03 | 2001-09-03 | Compounds |
GB0121303 | 2001-09-03 | ||
GB0130392 | 2001-12-19 | ||
GB0130331A GB0130331D0 (en) | 2001-12-19 | 2001-12-19 | Compounds |
GB0130331 | 2001-12-19 | ||
GB0130392A GB0130392D0 (en) | 2001-12-19 | 2001-12-19 | Compouds |
PCT/GB2002/002042 WO2002090355A1 (en) | 2001-05-05 | 2002-05-02 | N-aroyl cyclic amines |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60224521D1 true DE60224521D1 (de) | 2008-02-21 |
DE60224521T2 DE60224521T2 (de) | 2009-01-08 |
Family
ID=27516022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60224521T Expired - Lifetime DE60224521T2 (de) | 2001-05-05 | 2002-05-02 | Cyclische N-Aroylamine |
Country Status (20)
Country | Link |
---|---|
US (4) | US7432270B2 (de) |
EP (2) | EP1956020A3 (de) |
JP (1) | JP4309135B2 (de) |
KR (1) | KR20030096348A (de) |
CN (1) | CN100448874C (de) |
AR (1) | AR033306A1 (de) |
AT (1) | ATE383359T1 (de) |
AU (1) | AU2002253361B2 (de) |
BR (1) | BR0209334A (de) |
CA (1) | CA2446396A1 (de) |
CZ (1) | CZ20032990A3 (de) |
DE (1) | DE60224521T2 (de) |
ES (1) | ES2299567T3 (de) |
HU (1) | HUP0400048A3 (de) |
IL (1) | IL158463A0 (de) |
MX (1) | MXPA03010129A (de) |
NO (1) | NO20034925L (de) |
NZ (1) | NZ528851A (de) |
PL (1) | PL366853A1 (de) |
WO (1) | WO2002090355A1 (de) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002089800A2 (en) * | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
EP1705179A1 (de) * | 2001-06-28 | 2006-09-27 | Smithkline Beecham Plc | N-Aroyl Zyklische Aminderivate als Orexin Rezeptor Antagonisten |
GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0130335D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
ATE344261T1 (de) * | 2002-09-18 | 2006-11-15 | Glaxo Group Ltd | Cyclische n-aroylamine als orexinrezeptorantagonisten |
EP1554239B1 (de) | 2002-10-11 | 2011-01-26 | Actelion Pharmaceuticals Ltd. | Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste |
US7208504B2 (en) | 2002-10-12 | 2007-04-24 | Sanofi-Aventis Deutschland Gmbh | Bicyclic inhibitors of hormone sensitive lipase |
DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
GB0225938D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
DE602004011204T2 (de) | 2003-04-28 | 2008-12-24 | Actelion Pharmaceuticals Ltd. | Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. |
KR100848747B1 (ko) | 2004-03-01 | 2008-07-25 | 액테리온 파마슈티칼 리미티드 | 치환된 1,2,3,4-테트라하이드로이소퀴놀린 유도체 |
EP1734963A4 (de) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen |
WO2006007586A1 (en) * | 2004-07-01 | 2006-01-19 | Science & Technology Corporation @ Unm | Organocatalysts and methods of use in chemical synthesis |
US7501395B2 (en) | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
TW200716576A (en) * | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
EP1907384A2 (de) * | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr-agonisten |
DE102005049953A1 (de) | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
AU2007272854B2 (en) | 2006-07-14 | 2013-08-01 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
TW200823227A (en) * | 2006-09-29 | 2008-06-01 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
DE602007012142D1 (en) * | 2006-12-01 | 2011-03-03 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren |
TW200833328A (en) * | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
US8263586B2 (en) | 2007-05-18 | 2012-09-11 | Merck Sharp & Dohme Corp. | OXO bridged diazepan orexin receptor antagonists |
CA2687321C (en) | 2007-05-23 | 2013-10-08 | Merck & Co., Inc. | Pyridyl piperidine orexin receptor antagonists |
EP2150115B1 (de) | 2007-05-23 | 2013-09-18 | Merck Sharp & Dohme Corp. | Cyclopropylpyrrolidinorexin-rezeptorantagonisten |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
JP5546451B2 (ja) | 2007-06-04 | 2014-07-09 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト |
BRPI0813218A2 (pt) | 2007-07-03 | 2014-12-23 | Actelion Pharmaceuticals Ltd | Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. |
AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
KR20100046047A (ko) | 2007-07-27 | 2010-05-04 | 액테리온 파마슈티칼 리미티드 | 2-아자-비시클로[3.3.0]옥탄 유도체 |
EP2207778A2 (de) * | 2007-09-24 | 2010-07-21 | Actelion Pharmaceuticals Ltd. | Als orexinrezeptor-antagonisten geeignete pyrrolidine und piperidine |
NZ588080A (en) | 2008-02-21 | 2012-04-27 | Actelion Pharmaceuticals Ltd | 2-Aza-bicyclo[2.2.1]heptane derivatives |
GB0806536D0 (en) * | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
JP5301665B2 (ja) * | 2008-07-29 | 2013-09-25 | エフ.ホフマン−ラ ロシュ アーゲー | オレキシンアンタゴニストとしてのピロリジン−3−イルメチル−アミン |
WO2010038200A1 (en) * | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
JP2012506374A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト |
JP2012506375A (ja) * | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト |
EP2348857B1 (de) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Neue cyclische benzimidazolderivate als antidiabetika |
CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
WO2010063662A1 (en) * | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
UY32277A (es) * | 2008-12-02 | 2010-05-31 | Glaxo Group Ltd | Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos |
EP2275421A1 (de) | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro-Amino-Verbindungen geeignet zur Behandlung von unter anderem Schlafstörungen und Drogenabhängigkeit |
US20120149711A1 (en) * | 2009-08-24 | 2012-06-14 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EA201690035A1 (ru) | 2011-02-25 | 2016-05-31 | Мерк Шарп Энд Домэ Корп. | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов |
CA2754237A1 (en) | 2011-05-27 | 2012-11-27 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
WO2012166654A1 (en) * | 2011-05-27 | 2012-12-06 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
EP2811997B1 (de) | 2012-02-07 | 2018-04-11 | Eolas Therapeutics Inc. | Substituierte proline/piperidine als orexin-rezeptorantagonisten |
ITMI20120322A1 (it) * | 2012-03-01 | 2013-09-02 | Rottapharm Spa | Composti di 4,4-difluoro piperidina |
SI2855453T1 (sl) | 2012-06-04 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Benzimidazol-prolinski derivati |
EP2880028B1 (de) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetische tricyclische verbindungen |
EP2906553B1 (de) | 2012-10-10 | 2019-06-26 | Idorsia Pharmaceuticals Ltd | [ortho-bi(hetero)aryl]-[2-(meta-bi(hetero)aryl)-pyrrolidin-1-yl]-methanonderivative als orexinrezeptor-antagonisten |
US9586950B2 (en) | 2012-10-16 | 2017-03-07 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists |
WO2014085208A1 (en) * | 2012-11-27 | 2014-06-05 | Merck Sharp & Dohme Corp. | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists |
EP2970241A1 (de) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidinamidderivate als orexinrezeptor-antagonisten |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
EP2970384A1 (de) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonisten der guanylatcyclase und deren verwendungen |
EP2968439A2 (de) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Zusammensetzungen zur behandlung von magen-darm-störungen |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2017001954A (ja) * | 2013-11-08 | 2017-01-05 | 石原産業株式会社 | 含窒素飽和複素環化合物 |
SI3077389T1 (en) | 2013-12-03 | 2018-01-31 | Idorsia Pharmaceuticals Ltd | (S) - (2- (6-CHLORO-7-METHYL-1 H-BENZO (D) IMIDAZOL-2-YL) -2-METHYLPYROLIDIN-1-YL (5-METHOXY-2- (2H- , 2,3-TRIAZOL-2-IL) PHENYL) METHANONE AND ITS USE AS ANTAGONISTS OF OREXIN RECEPTOR |
UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
DK3077391T3 (en) | 2013-12-04 | 2018-10-22 | Idorsia Pharmaceuticals Ltd | USE OF BENZIMIDAZOLE PROLINE DERIVATIVES |
JP2017024990A (ja) * | 2013-12-13 | 2017-02-02 | 大正製薬株式会社 | オキサゾリジン及びオキサジナン誘導体 |
WO2015087853A1 (ja) * | 2013-12-13 | 2015-06-18 | 大正製薬株式会社 | オキサジナン化合物の結晶形及びその製造方法 |
ES2901418T3 (es) * | 2014-08-13 | 2022-03-22 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores del receptor de orexina |
WO2016095204A1 (en) | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor antagonists |
AU2017217931B2 (en) | 2016-02-12 | 2020-10-22 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
US20190151304A1 (en) | 2016-05-10 | 2019-05-23 | Inserm (Institut National De La Santé Et De La Rechercjae Médicale | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
EP3558298A4 (de) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Antidiabetische spirochromanverbindungen |
WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
WO2023218023A1 (en) | 2022-05-13 | 2023-11-16 | Idorsia Pharmaceuticals Ltd | Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5462856A (en) | 1990-07-19 | 1995-10-31 | Bunsen Rush Laboratories, Inc. | Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins |
JP3810097B2 (ja) * | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | ピロリジン−2−イルカルボニル複素環式化合物誘導体 |
WO1996034877A1 (en) | 1995-05-05 | 1996-11-07 | Human Genome Sciences, Inc. | Human neuropeptide receptor |
US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
AR016817A1 (es) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
US6372757B1 (en) | 1998-05-08 | 2002-04-16 | Smithkline Beecham P.L.C. | Phenylurea and phenylthio urea derivatives |
JP4511042B2 (ja) | 1998-08-07 | 2010-07-28 | メルク セローノ ソシエテ アノニム | 不妊症の治療のためのfsh模倣物 |
CA2341678C (en) | 1998-09-01 | 2009-10-13 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
ES2231158T3 (es) | 1999-02-12 | 2005-05-16 | Smithkline Beecham Plc | Derivados y fenil urea y fenil tiourea. |
EP1150977B1 (de) | 1999-02-12 | 2004-08-25 | SmithKline Beecham plc | Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten |
WO2000047576A1 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
JP2003500383A (ja) | 1999-05-24 | 2003-01-07 | コア・セラピューティクス,インコーポレイテッド | 第Xa因子阻害剤 |
MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
AU2001272476A1 (en) * | 2000-06-16 | 2001-12-24 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
JP4246490B2 (ja) | 2000-11-28 | 2009-04-02 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体のアンタゴニストとしてのモルホリン誘導体 |
WO2002089800A2 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
EP1705179A1 (de) | 2001-06-28 | 2006-09-27 | Smithkline Beecham Plc | N-Aroyl Zyklische Aminderivate als Orexin Rezeptor Antagonisten |
ATE344261T1 (de) | 2002-09-18 | 2006-11-15 | Glaxo Group Ltd | Cyclische n-aroylamine als orexinrezeptorantagonisten |
JP5301665B2 (ja) * | 2008-07-29 | 2013-09-25 | エフ.ホフマン−ラ ロシュ アーゲー | オレキシンアンタゴニストとしてのピロリジン−3−イルメチル−アミン |
-
2002
- 2002-05-02 EP EP07150263A patent/EP1956020A3/de not_active Withdrawn
- 2002-05-02 AR ARP020101610A patent/AR033306A1/es unknown
- 2002-05-02 AT AT02722482T patent/ATE383359T1/de not_active IP Right Cessation
- 2002-05-02 HU HU0400048A patent/HUP0400048A3/hu unknown
- 2002-05-02 BR BR0209334-0A patent/BR0209334A/pt not_active IP Right Cessation
- 2002-05-02 CN CNB02811986XA patent/CN100448874C/zh not_active Expired - Fee Related
- 2002-05-02 CZ CZ20032990A patent/CZ20032990A3/cs unknown
- 2002-05-02 PL PL02366853A patent/PL366853A1/xx not_active Application Discontinuation
- 2002-05-02 KR KR10-2003-7014375A patent/KR20030096348A/ko not_active Application Discontinuation
- 2002-05-02 DE DE60224521T patent/DE60224521T2/de not_active Expired - Lifetime
- 2002-05-02 AU AU2002253361A patent/AU2002253361B2/en not_active Ceased
- 2002-05-02 ES ES02722482T patent/ES2299567T3/es not_active Expired - Lifetime
- 2002-05-02 EP EP02722482A patent/EP1385845B1/de not_active Expired - Lifetime
- 2002-05-02 CA CA002446396A patent/CA2446396A1/en not_active Abandoned
- 2002-05-02 MX MXPA03010129A patent/MXPA03010129A/es active IP Right Grant
- 2002-05-02 NZ NZ528851A patent/NZ528851A/xx unknown
- 2002-05-02 WO PCT/GB2002/002042 patent/WO2002090355A1/en active IP Right Grant
- 2002-05-02 US US10/477,008 patent/US7432270B2/en not_active Expired - Fee Related
- 2002-05-02 JP JP2002587434A patent/JP4309135B2/ja not_active Expired - Fee Related
- 2002-05-02 IL IL15846302A patent/IL158463A0/xx unknown
-
2003
- 2003-11-04 NO NO20034925A patent/NO20034925L/no not_active Application Discontinuation
-
2007
- 2007-10-26 US US11/925,036 patent/US20090093478A1/en not_active Abandoned
- 2007-10-26 US US11/925,129 patent/US7919507B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/926,221 patent/US7741329B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE383359T1 (de) | N-aroyl zyklische amine | |
IS7716A (is) | Hringlaga heterósambönd | |
ATE548938T1 (de) | Zahnbürste | |
DK1405852T3 (da) | Diaminderivater | |
ATE513491T1 (de) | Zahnbürste | |
IS8320A (is) | N-staðgengnir pýrasólýl-amidýl-bensimidasólýl | |
HK1073312A1 (en) | Cyclic amine compound | |
NO20014597D0 (no) | Fremgangsmåte | |
NO20040877L (no) | Cyklisk aminforbindelse. | |
DE60023568D1 (de) | Spannvorrichtung | |
DE60107036D1 (de) | Spannvorrichtung | |
FR2824678B1 (fr) | Alternateur | |
ATE514681T1 (de) | N-substituierte pyrazolylcarboxanilide | |
DE60110046D1 (de) | Cyclische hexapeptidderivate | |
DE60214294D1 (de) | Wechselstromgenerator | |
ATE309231T1 (de) | Antipsychotische n-aralkyl cyclische amine | |
DE60102635D1 (de) | Spannvorrichtung | |
DE60210813D1 (de) | Zahnbürste | |
ATA14732002A (de) | Spannvorrichtung | |
DE10111783B4 (de) | Einspritzdüse | |
FR2820559B1 (fr) | Alternateur | |
DE50212755D1 (de) | Bohrfutter | |
DE50208514D1 (de) | Spannvorrichtung | |
NO20033586L (no) | Tannbörste | |
ATE296652T1 (de) | Spritze |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8381 | Inventor (new situation) |
Inventor name: BRANCH, CLIVE, LESLIE, HARLOW, ESSEX, GB Inventor name: COULTON, STEVEN, HARLOW, ESSEX, GB Inventor name: JOHNS, AMANDA, HARLOW, ESSEX, GB Inventor name: JOHNSON, CHRISTOPHER, NORBERT, HARLOW, ESSEX, GB Inventor name: PORTER, RODERICK, ALAN, HARLOW, ESSEX, GB Inventor name: STEMP, GEOFFREY, HARLOW, ESSEX, GB Inventor name: THEWLIS, KEVIN, HARLOW, ESSEX, GB |
|
8364 | No opposition during term of opposition |